The scientist’s investigation covers issues in Internal medicine, Surgery, Abiraterone acetate, Prostate cancer and Urology. His work carried out in the field of Internal medicine brings together such families of science as Immunology, Gastroenterology and Oncology. His work in Surgery addresses subjects such as Follicular lymphoma, which are connected to disciplines such as Survival rate, Radioimmunotherapy and Ibritumomab tiuxetan.
Arturo Molina regularly links together related areas like Docetaxel in his Abiraterone acetate studies. His Prostate cancer research incorporates elements of Endocrinology and Circulating tumor cell. His study in Urology is interdisciplinary in nature, drawing from both Androgen deprivation therapy, Apalutamide, Placebo and Performance status.
His primary areas of study are Internal medicine, Abiraterone acetate, Oncology, Prostate cancer and Surgery. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology. His Abiraterone acetate study combines topics in areas such as Urology, Placebo, Androgen, Docetaxel and Prednisone.
His research in Urology tackles topics such as Orteronel which are related to areas like CYP17A1 Inhibitor and Antiandrogen. His work in Prostate cancer tackles topics such as Circulating tumor cell which are related to areas like Cancer biomarkers. In his study, Proportional hazards model is inextricably linked to Hazard ratio, which falls within the broad field of Surgery.
Arturo Molina focuses on Internal medicine, Prostate cancer, Abiraterone acetate, Oncology and Prednisone. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. His studies deal with areas such as Endocrinology, Clinical trial and Chemotherapy as well as Prostate cancer.
Arturo Molina interconnects Surgery, Urology, Placebo, Docetaxel and Hazard ratio in the investigation of issues within Abiraterone acetate. His studies in Surgery integrate themes in fields like Adverse effect and Confidence interval. His Oncology research includes elements of Post-hoc analysis, Prospective cohort study, Cancer biomarkers and Circulating tumor cell.
Abiraterone acetate, Prostate cancer, Internal medicine, Oncology and Prednisone are his primary areas of study. The various areas that Arturo Molina examines in his Abiraterone acetate study include Endocrinology, Surgery, Urology, Docetaxel and Testosterone. In Surgery, Arturo Molina works on issues like Hazard ratio, which are connected to Survival rate and Gastroenterology.
His research investigates the connection with Prostate cancer and areas like Chemotherapy which intersect with concerns in Discontinuation and Confidence interval. His biological study focuses on Phases of clinical research. His Oncology research is multidisciplinary, incorporating elements of Cancer, Cancer biomarkers, Post-hoc analysis, Proportional hazards model and Prospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi.
The New England Journal of Medicine (2011)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina.
The New England Journal of Medicine (2013)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis.
Lancet Oncology (2012)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad.
Lancet Oncology (2015)
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
Elise Olsen;Madeleine Duvic;Arthur Frankel;Youn Kim.
Journal of Clinical Oncology (2001)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker.
Journal of Clinical Oncology (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid.
Cancer Research (2009)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila;Michael J. Morris;Johann S. De Bono;Charles J. Ryan.
Journal of Clinical Oncology (2010)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H.M. Reid;Gerhardt Attard;Daniel C. Danila;Nikhil Babu Oommen.
Journal of Clinical Oncology (2010)
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
Koen Van Besien;Fausto R. Loberiza;Ruta Bajorunaite;James O. Armitage.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: